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incidence of which might be expected 
to be higher in immunocompromised 
patients given JAK inhibitors.
In conclusion, we believe that, 
beyond the intriguing opportunity to 
directly block the penetration of SARS-
CoV-2 into the cell, the use of baricitinib 
in susceptible patients with ongoing 
pneumonia associated with COVID-19 
should be considered with extreme 
caution.
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Baricitinib for COVID-19: 
a suitable treatment?
As rheumatologists used to treating 
rheumatoid arthritis with Janus 
kinase (JAK) inhibitors and working 
in an area (Lombardy, Italy) with a 
high incidence of coronavirus disease 
2019 (COVID-19), we read with great 
interest the Comment in The Lancet 
Infectious Diseases by Justin Stebbing 
and colleagues1 about the potential 
use of baricitinib for severe acute 
respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection. The described 
mechanism affecting viral endocytosis 
mediated by two members of the 
numb-associated kinase family is one 
of the many unfamiliar effects of a 
relatively recent drug class, the real 
safety profile of which still remains to 
be definitively clarified. Undoubtedly, 
the fact that baricitinib can provide 
this antiviral effect at the approved 
dose for rheumatoid arthritis therapy 
is an undeniable advantage over 
other potential inhibitors of the same 
pathway.
However, some concern could arise 
from the best-known aspects of the 
mechanism of action of the drug and 
its safety profile. Interferon is one of 
the most powerful innate immune 
responses to prevent viral replication 
during the early phases of infection. 
Transcription through the JAK–STAT 
signalling pathway (mainly mediated 
by JAK1 and JAK2), activated by 
interferons, leads to the upregulation 
of many interferon-controlled genes 
that quickly kill viruses in infected 
cells. The importance of this defense 
mechanism is confirmed by the fact 
that most viruses have developed 
strategies to counteract the effects 
of interferons by blocking their 
signalling pathway, and viral-encoded 
factors that antagonise the JAK–STAT 
pathway are crucial determinants 
of virulence.2 As a consequence, 
JAK–STAT signal blocking by baricitinib 
(a selective JAK1 and JAK2 inhibitor) 
produces an impairment of interferon-
mediated antiviral response, with a 
potential facilitating effect on the 
evolution of SARS-CoV-2 infection. 
This mechanism is thought to be 
involved in an increased risk of herpes 
zoster and simplex infection, which 
was reported in the development 
programme of baricitinib 4 mg com-
pared with placebo (herpes zoster 
4·2 per 100 person-years vs 1·0 per 
100 person-years [p<0·05]; herpes 
simplex 5·4 per 100 person-years vs 
2·2 per 100 person-years [p<0·05]).3 
Notably, this complication also seems 
to be shared by the new JAK1 selective 
inhibitors upadacitinib and filgotinib.4 
Viral infections (including herpes 
zoster and herpes simplex) in intensive 
care units can account for up to 10% of 
community-acquired and up to 5% of 
ventilator-associated pneumonia,5 the 
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